Sclerostin Regulates Release of Bone Mineral by Osteocytes by Induction of Carbonic Anhydrase 2
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The osteocyte product sclerostin is emerging as an important paracrine regulator of bone mass. It has recently been shown that osteocyte production of receptor activator of NF-κB ligand (RANKL) is important in osteoclastic bone resorption, and we reported that exogenous treatment of osteocytes with sclerostin can increase RANKL-mediated osteoclast activity. There is good evidence that osteocytes can themselves liberate mineral from bone in a process known as osteocytic osteolysis. In the current study, we investigated sclerostin-stimulated mineral dissolution by human primary osteocyte-like cells (hOCy) and mouse MLO-Y4 cells. We found that sclerostin upregulated osteocyte expression of carbonic anhydrase 2 (CA2/Car2), cathepsin K (CTSK/Ctsk), and tartrate-resistant acid phosphatase (ACP5/Acp5). Because acidification of the extracellular matrix is a critical step in the release of mineral from bone, we further examined the regulation by sclerostin of CA2. Sclerostin stimulated CA2 mRNA and protein expression in hOCy and in MLO-Y4 cells. Sclerostin induced a decrease in intracellular pH (pHi) in both cell types as well as a decrease in extracellular pH (pHo) and the release of calcium ions from mineralized substrate. These effects were reversed in the co-presence of the carbonic anhydrase inhibitor, acetozolamide. Car2-siRNA knockdown in MLO-Y4 cells significantly inhibited the ability of sclerostin to both reduce the pHo and release calcium from a mineralized substrate. Knockdown in MLO-Y4 cells of each of the putative sclerostin receptors, Lrp4, Lrp5 and Lrp6, using siRNA, inhibited the sclerostin induction of Car2, Catk and Acp5 mRNA, as well as pHo and calcium release. Consistent with this activity of sclerostin resulting in osteocytic osteolysis, human trabecular bone samples treated ex vivo with recombinant human sclerostin for 7 days exhibited an increased osteocyte lacunar area, an effect that was reversed by the co-addition of acetozolamide. These findings suggest a new role for sclerostin in the regulation of perilacunar mineral by osteocytes. © 2013 American Society for Bone and Mineral Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evidence for osteocyte regulation of bone homeostasis through RANKL expression
Nakashima, T., Hayashi, M., Fukunaga, T., Kurata, K., Oh-hora, M., Feng, J. Q., Bonewald, L. F., Kodama, T., Wutz, A., Wagner, E. F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2452 · Cited by 1,778
Self-citationSclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366 · cited 8×
“(55) The dependence of the effects of sclerostin, at least in MLO‐Y4 cells, on LRP5/6 expression suggests that Wnt signaling inhibition may be at least partly responsible for the effects of sclerostin reported here because these are the Wnt co‐receptors that facilitate canonical b‐catenin signaling.”
BackgroundInfluentialMechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin
Robling, A. G., Niziolek, P. J., Baldridge, L. A., Condon, K. W., Allen, M. R., Alam, I., Mantila, S. M., Gluhak-Heinrich, J., Bellido, T. M., Harris, S. E., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705092200 · Cited by 1,350 · cited 1×
“Sclerostin has also been reported to be upregulated under other conditions, such as mechanical unloading,((39,41)) glucocorticoid treatment,((59)) and in response to 1,25(OH)2‐ vitamin D3 alone or in combination with retinoic acid.”
BackgroundMatrix-embedded cells control osteoclast formation
Xiong, J., Onal, M., Jilka, R. L., Weinstein, R. S., Manolagas, S. C., & O'Brien, C. A. (2011) · Nature Medicine · doi:10.1038/nm.2448 · Cited by 1,304 · cited 1×
“In addition to this anti‐anabolic role, sclerostin was also found to stimulate osteocyte support of osteoclastogenesis in a RANKL‐dependentmanner,((13)) consistent with the recent demonstration that osteocytes are a major source of RANKL in post‐developmental bone.((14,15)) It is therefore now apparent that osteocytes…”
ResultIncreased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147 · cited 1×
“Mutations of the SOST gene have been identified as causative in sclerosteosis, a high bone mass disease in humans.((3,4)) A 52‐kb deletion of a regulatory region approximately 35 kb distal to the SOST gene is causative of the high bone mass phenotype seen in Van Buchem’s disease.”
BackgroundBrunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011 · cited 1×
“Mutations of the SOST gene have been identified as causative in sclerosteosis, a high bone mass disease in humans.((3,4)) A 52‐kb deletion of a regulatory region approximately 35 kb distal to the SOST gene is causative of the high bone mass phenotype seen in Van Buchem’s disease.”
BackgroundSclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor
Semënov, M., Tamai, K., & He, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504308200 · Cited by 771
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Lacza, C., Dioszegi, M., Dikkers, F. G., Hildering, P., Willems, P. J., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.2.91 · Cited by 698 · cited 1×
“A 52‐kb deletion of a regulatory region approximately 35 kb distal to the SOST gene is causative of the high bone mass phenotype seen in Van Buchem’s disease.((5,6)) Deletion of Sost in mice also causes a striking, whole skeleton, high bone mass phenotype similar to that of sclerosteosis in humans.”
BackgroundSclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Wijenayaka, A. R., Kogawa, M., Lim, H. P., Bonewald, L. F., Findlay, D. M., & Atkins, G. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025900 · Cited by 503 · cited 6×
“We have reported that osteocytes and pre‐osteocytes are likely cellular targets for the activity of sclerostin.((12,13)) Sclerostin in these cell types exerted anti‐anabolic effects, such as increasing the expression of the mineralization inhibitory MEPE‐ASARM peptides,((12)) as well as pro‐catabolic effects through s…”
BackgroundResultSelf-citation
Cited by
Subchondral bone microenvironment in osteoarthritis and pain
Hu, Y., Chen, X., Wang, S., Jing, Y., & Su, J. (2021) · Bone Research · doi:10.1038/s41413-021-00147-z · Cited by 577
Han, Y., You, X., Xing, W., Zhang, Z., & Zou, W. (2018) · Bone Research · doi:10.1038/s41413-018-0019-6 · Cited by 576
Robling, A. G., & Bonewald, L. F. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021119-034332 · Cited by 539
“Adding sclerostin to MLO-Y4 cells or to primary human osteocytes induces the expression of perilacunar remodeling genes such as cathepsin K, carbonic anhydrase 2, and matrix metalloproteinase 13 (49).”
BackgroundRecker, R. R., Benson, C. T., Matsumoto, T., Bolognese, M. A., Robins, D. A., Alam, J., Chiang, A. Y., Hu, L., Krege, J. H., Sowa, H., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2351 · Cited by 293
Dole, N. S., Mazur, C. M., Acevedo, C., Lopez, J. P., Monteiro, D. A., Fowler, T. W., Gludovatz, B., Walsh, F., Regan, J. N., Messina, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.115 · Cited by 173
Jähn, K., Kelkar, S., Zhao, H., Xie, Y., Tiede-Lewis, L. M., Dusevich, V., Dallas, S. L., & Bonewald, L. F. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3167 · Cited by 116
“Thishasbeensuggestedby the work from Kogawa and colleagues((27)) demonstrating sclerostin regulation of carbonic anhydrase 2, an enzyme needed for proton generation, in osteocytic cells in vitro.”
BackgroundSelf-citationPTH signaling mediates perilacunar remodeling during exercise
Gardinier, J. D., Al-Omaishi, S., Morris, M. D., & Kohn, D. H. (2016) · Matrix Biology · doi:10.1016/j.matbio.2016.02.010 · Cited by 69
“To facilitate perilacunar remodeling, osteocytes can dissolve the surrounding mineral to enlarge their lacuna space by increasing acidity and degrading the mineral and matrix through tartrate-resistant acid phosphatase (TRAP), cathepsin-k (Ctsk), carbonic anhydrase 2 (CaII), and matrix metalloproteinase (MMP) activity…”
BackgroundThe local production of 1,25(OH)2D3 promotes osteoblast and osteocyte maturation
Turner, A. G., Hanrath, M. A., Morris, H. A., Atkins, G. J., & Anderson, P. H. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.10.003 · Cited by 57
Self-citationClarke, M. V., Russell, P. K., Findlay, D. M., Sastra, S., Anderson, P. H., Skinner, J. P., Atkins, G. J., Zajac, J. D., & Davey, R. A. (2015) · Endocrinology · doi:10.1210/en.2015-1345 · Cited by 54
“Five-micron-thick sections from decalcified left femurs were stained with toluidine blue for osteocyte lacunar area (28).”
MethodSelf-citationThe Role of Sclerostin in Bone and Ectopic Calcification
De Maré, A., D’Haese, P. C., & Verhulst, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093199 · Cited by 45
“The proteins that are upregulated by sclerostin correspond to those produced by the osteoclasts, including carbonic anhydrase 2 [43], cathepsin K [43,44], tartrate-resistant acid phosphatase [43,44] and C-terminal collagen telopeptide [31].”
BackgroundDedic, C., Hung, T. S., Shipley, A. M., Maeda, A., Gardella, T., Miller, A. L., Divieti Pajevic, P., Kunkel, J. G., & Rubinacci, A. (2018) · Bone · doi:10.1016/j.bone.2018.07.020 · Cited by 14
“mineralized matrix without the need to activate an osteoclast-like function of matrix lysis (35) since they are ideally placed to establish a direct and extensive contact to a mineralized matrix (36, 37); can regulate virtually every phase of the mineralization process (36); can dissolve minerals through canaliculi by…”
Hongo, H., Hasegawa, T., Saito, M., Tsuboi, K., Yamamoto, T., Sasaki, M., Abe, M., Henrique Luiz de Freitas, P., Yurimoto, H., Udagawa, N., et al. (2020) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155420961375 · Cited by 12
“For histological examination, other wild-type mice were anesthetized as described above and were then injected with 80 μg/kg/dose of hPTH [1-34] directly into the external jugular vein, whereas control mice were injected with the same volume of PBS.”
BackgroundMethodInfluential
Metadata
- Authors
- Kogawa, M., Wijenayaka, A. R., Ormsby, R. T., Thomas, G. P., Anderson, P. H., Bonewald, L. F., Findlay, D. M., & Atkins, G. J.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-06-05
- Volume
- 28
- Issue
- 12
- Pages
- 2436-2448
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1709742880
- Cited by
- 153
- References
- 16
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.